Showing results (41-50 of 99) with videos related to
Sort By:
Pageof 10
Fortschritte Der Neurologie-Psychiatrie|November 1, 1995
[Panic disorder and agoraphobia: what is effective?]B Bandelow, K Sievert, M Röthemeyer, et al.Pharmacopsychiatry|February 12, 2005
Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challengesG Kronenberg, P Berger, R F Tauber, et al.Neuroreport|September 8, 2000
Plasma homocysteine is a predictor of alcohol withdrawal seizuresS Bleich, D Degner, B Bandelow, et al.European Biophysics Journal : EBJ|January 1, 1984
Investigation of pH-induced symmetry distortions of the prosthetic group in oxyhaemoglobin by resonance Raman scatteringR Schweitzer-Stenner, W Dreybrodt, D Wedekind, et al.Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|May 2, 2013
Clock gene expression in the liver of streptozotocin-induced and spontaneous type 1 diabetic ratsK Hofmann, U Schönerstedt, E Mühlbauer, et al.Neuropsychobiology|January 1, 1997
Endocrine correlates of personality traits: a comparison between emotionally stable and emotionally labile healthy young menL Adler, D Wedekind, J Pilz, et al.Journal of Pineal Research|September 21, 2011
Catecholamines are the key for explaining the biological relevance of insulin-melatonin antagonisms in type 1 and type 2 diabetesE Peschke, K Hofmann, K Pönicke, et al.Psychiatry Research|March 10, 2000
The use of the Panic and Agoraphobia Scale in a clinical trialB Bandelow, E Brunner, A Broocks, et al.Pharmacopsychiatry|October 1, 1998
Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamineJ Sandmann, B Lörch, B Bandelow, et al.European Archives of Psychiatry and Clinical Neuroscience|September 5, 1998
Rebound insomnia after hypnotic withdrawal in insomniac outpatientsG Hajak, P Clarenbach, W Fischer, et al.Pageof 10